➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Moodys
Express Scripts
Mallinckrodt
Johnson and Johnson

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Litigation Details for Plaintiff(s) v. Defendant(s) (D. Del. 2019)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Plaintiff(s) v. Defendant(s)
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Plaintiff(s) v. Defendant(s) (D. Del. 2019)

Date Filed Document No. Description Snippet Link To Document
2018-09-21 1168 prior to the expiration of U.S. Patent No. 9,957,232 (the “’232 patent”). As set forth in its… The ’232 Patent 25. U.S. Patent No. 9,957,232, entitled “… 1. This is an action for patent infringement under the patent laws of the United States, Title…forth in greater detail in the ’232 patent, the claims of the ’232 patent, incorporated by reference herein…the ’232 patent. 31. Apotex had knowledge of the claims of the ’232 patent before External link to document
0000-00-00 1674 Complaint of U.S. Patents Nos. 8,101,659 (the “’659 patent”), 8,796,331 (the “’331 patent”), 8,877,938 (the “’938…’938 patent”), and/or 9,388,134 (the “’134 patent”). PARTIES… THE PATENTS-IN-SUIT AND ENTRESTO® 178. Novartis is the owner of the ’659 patent, titled…copy of the ’659 patent is attached hereto as Exhibit A. 179. The ’659 patent claims, inter alia…the ’331 patent, titled “Methods of treatment and pharmaceutical composition.” The ’331 patent was duly External link to document
0000-00-00 1713 Complaint of U.S. Patents Nos. 8,101,659 (the “’659 patent”), 8,796,331 (the “’331 patent”), 8,877,938 (the “’938…’938 patent”), and/or 9,388,134 (the “’134 patent”). ME1 31784564v.1 Case 1:99-mc-09999 Document 1713… THE PATENTS-IN-SUIT AND ENTRESTO® 57. Novartis is the owner of the ’659 patent, titled…copy of the ’659 patent is attached hereto as Exhibit A. 58. The ’659 patent claims, inter…the ’331 patent, titled “Methods of treatment and pharmaceutical composition.” The ’331 patent was duly External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Harvard Business School
Merck
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.